Scalper1 News
Pharmacyclics (PCYC) announced Tuesday that a late-stage trial of its blood-cancer drug Imbruvica will be stopped early, as it has already proven its effectiveness. Pharmacyclics stock jumped 19% in morning trading in the stock market today. The trial in question was comparing survival rates in patients with refractory chronic lymphocytic leukeumia (CLL) or small lymphocytic lymphoma who were treated with Imbruvica vs. those treated with current Scalper1 News
Scalper1 News